Zolpidem: Distinct from triazolam?

Annals of Pharmacotherapy

Volumn 31, Issue 5, 1997, Pages 625-632

  Lobo, Bob L ^a,b   Greene, William L ^a,c  

^a Department of Pharmacy   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

triazolam; Zolpidem

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE RECEPTOR; CHLORPROMAZINE; CIMETIDINE; DILTIAZEM; ERYTHROMYCIN; FLUOXETINE; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; NEFAZODONE; ORAL CONTRACEPTIVE AGENT; RANITIDINE; TRIAZOLAM; ZOLPIDEM;

AMNESIA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INSOMNIA; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REVIEW;

EID: 0030947548     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100518     Document Type: Review

References (52)

1. Walsh JK, Engelhardt CL. Trends in the pharmacologic treatment of insomnia. J Clin Psychiatry 1992;53:12 (suppl):10-7.
2. Dopheide JA. Sleep disorders. In: Young LY, KodaKimble MA, eds. Applied therapeutics: the clinical use of drugs. Vancouver WA: Applied Therapeutics Inc., 1995:74.
3. Top 200 drugs of 1995. Pharm Times 1996;April:27-36.
4. Klett CJ. Review of triazolam data, J Clin Psychiatry 1992;53:12(suppl):61-7.
5. Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992;53:12(suppl):34-9.
6. Product information. Ambien (zolpidem tartrate). Chicago: G.D. Searle & Company, April 1994.
7. Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Clin Pharmacokinet 1995;29:142-53.
8. Metzler CM, Royer ME, Veldkamp W, Linet OI. Bioavailability and pharmacokinetics of orally administered triazolam in normal subjects (abstract). Clin Pharmacol Ther 1977;21:111-2.
9. Product information. Halcion (triazolam). Kalamazoo, MI: The Upjohn Company, July 1993.
10. Bianchetti G, Dubruc C, Thiercelin JF, Bercoff E, Bouchet JL, Emeriau JP, et al. Clinical pharmacokinetics of zolpidem in various physiological and pathological conditions. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:155-63.
11. Pichard L, Gillet G, Bonfils C, Domergue J, Thenot JP, Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome. Drug Metab Dispos 1995;23:1253-62.
12. Langer SZ, Arbilla S, Scatton B, Niddam R, Dubois A. Receptors involved in the mechanism of action of zolpi- dem. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:55-70.
13. Zivkovic B, Perrault G, Morel E, Sanger DJ. Comparative pharmacology of zolpidem and other hypnotics and sleep inducers. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:97-109.
14. Sanger DJ, Joly D, Zivkovic B. The behavioral pharmacology of zolpidem: Comparisons with other compounds acting at the benzodiazepine receptor. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:111-21.
15. Rosenberg J, Ahlstrom F. Randomized, double-blind trial of zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice. Scand J Prim Health Care 1994;12(2):88-92.
16. Pagot R, Cramer P, L'heritier C, Coquelin JP, Attali P. Comparison of the efficacy and tolerability of zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients. Curr Ther Res 1993;53:88-97.
17. Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993;15:127-36.
18. Louvel E, Cramer P, Ferreri M, Pagot R, Regnier F, Heritier CL, et al. Zolpidem and triazolam: long-term multicenter studies (1-3 months) in psychiatric and general practice patients. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:327-37.
19. Jonas JM, Coleman BS, Sherida AQ, Kalinske RW. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiatry 1992;53:12(suppl):19-31.
20. Gillin CJ, Byerley WF. The diagnosis and management of insomnia. N Engl J Med 1990;322:239-47.
21. Wheatley D. Prescribing short-acting hypnosedatives - current recommendations from a safety perspective. Drug Saf 1992;7:106-15.
22. Bartholini G. Growing aspects of hypnotic drugs. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:1-9.
23. Bond A. The risks of taking benzodiazepines. In: Hallstrom C, ed. Benzodiazepine dependence. Oxford: Oxford University Press, 1993:35-45.
24. Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry 1992;53:12(suppl):4-7.
25. Greenblatt DJ Harmatz JS, Shader RI. Does zolpidem have unique clinical properties? A pharmacodynamic comparison with triazolam and placebo (abstract). Clin Pharmacol Ther 1996;59:178.
26. Wesensten NJ, Balkin TJ, Belenky GL. Effects of daytime administration of zolpidem and triazolam on performance. Aviat Space Environ Med 1996;67(2):115-20.
27. Wesensten NJ, Balkin TJ, Belenky GL. Effects of daytime administration of zolpidem versus triazolam on memory. Eur J Clin Pharmacol 1995;48:115-22.
28. Berlin I, Warot D, Hergueta T, Molinier P, Bagot C, Puech AJ. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 1993;13:100-6.
29. Morselli PL, Larribaud J, Guillet P, Thiercelin JF, Barthelet G, Grilliat JP, et al. Daytime residual effects of zolpidem: a review of available data. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:183-91.
30. Bergougnan L, Hippius H, Ruther E, Lund R, Keilinger M, Speieri A, et al. Study on polysomnographic and daytime residual effects after single doses of zolpidem, triazolam, lormetazepam, and placebo in healthy volunteers (abstract). J Sleep Res 1992;1(suppl):21.
31. Lund R, Ruther E, Wober W, Hippius H. Effects of zolpidem (10 and 20 mg), lormetazepam, triazolam, and placebo on night sleep and residual effects during the day. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:193-203.
32. Wesensten NJ, Balkin TJ, Davis HQ, Belenky GL. Reversal of triazolam- and zolpidem-induced memory impairment by flumazenil. Psychopharmacology 1995;121:242-9.
33. Lader M. Historical development of the concept of tranquillizer dependence. In: Hallstrom C, ed. Benzodiazepine dependence. Oxford: Oxford University Press, 1993:46-57.
34. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia - a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994;27:166-75.
35. Monti JM, Monti D, Attali P. Comparative hypnotic and withdrawal effects of zolpidem, triazolam, and placebo in insomniac patients (abstract). J Sleep Res 1992;1(suppl):153.
36. Higgitt A, Fonagy P. Benzodiazepine dependence syndromes and syndromes of withdrawal. In: Hallstrom C, ed. Benzodiazepine dependence. Oxford: Oxford University Press, 1993:58-70.
37. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990;255:1246-55.
38. Cavallaro R, Regazzetti MG, Covelli G. Tolerance and withdrawal with zolpidem. Lancet 1993;342:374-5.
39. Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology 1983;80:275-8.
40. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther 1984;36:683-90.
41. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996;59:369-75.
42. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995;58:127-31.
43. Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986;6:297-9.
44. Wright CE, Lasher-Sisson TA, Swanson CN. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103-6.
45. Greenblatt DJ, von Moltke LL, Harmatz LS, Harrel LM, Tobias S, Shader RI, et al. Interaction of triazolam and ketoconazole (letter). Lancet 1995;345:191.
46. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
47. Ochs HR, Greenblatt DJ, Knuchel M. Differential effects of isoniazid on triazolam metabolism and oxazepam conjugation. Br J Clin Pharmacol 1983;16:743-6.
48. Greene DS, Dockens RC, Salazar DE, Barbaiya RH. Coadministration of nefazodone and benzodiazepines I: pharmacokinetic assessment (abstract). Clin Pharmacol Ther 1994;55:141.
49. 2 antagonists, cimetidine and ranitidine. Int J Clin Pharmacol Res 1988;8:471-6.
50. Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF. Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology 1988;96:63-6.
51. Halcion 8500-patient post-marketing study final technical reports being prepared for submission to the FDA. F-D-C Rep 1996;June 10:5.
52. Halcion safety, efficacy data should be reviewed anew by FDA advisory cmte; Upjohn criminal investigation should go to justice - FDA task force. F-D-C Rep 1996;June 3:5.